AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 62 min read$BIAF

bioAffinity Technologies, Inc. (BIAF): Nearly 90% increase in number of physician offices using CyPath Lung Utilization expands as physicians who ordered CyPath Lung in 2025 increase usage by…

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 Nearly 90% increase in number of physician offices using CyPath Lung Utilization expands as physicians who ordered CyPath Lung in 2025 increase usage by ne

Original reporting
SEC EDGAR 8-K
Published Oct 6, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BIAF
Bullish
high confidence
Mentioned
$BIAF
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BIAFBullishMed
01

Why it matters

The disclosed sales surge signals strong market traction, likely prompting short‑term buying interest.

02

Market read

First‑time disclosure of rapid adoption; could move the micro‑cap stock.

03

What to watch

Potential regulatory changes to LDTs could affect future scalability.

Relevance 6/10Novelty 7/10Timing: today

Background

bioAffinity Technologies (Nasdaq: BIAF) develops non‑invasive lung‑cancer tests using flow cytometry and AI.

Company-level read

Ticker impact

$BIAFBullishHigh confidence
Context

SEC 8‑K reports CyPath® Lung sales up >100% YoY and physician usage up 89% in Q3 2026, a fresh disclosure.

Expected impact

upward pressure as investors price in accelerated adoption

Evidence & confidence

First‑time reporting of double‑digit sales growth and expanding physician base suggests strong demand and potential revenue expansion.

Market effects

Sector

Boosts outlook for non‑invasive lung‑cancer diagnostics and related AI‑driven health‑tech firms.

Regional

May improve sentiment for US biotech small‑caps.

Global

Limited to niche diagnostic market; no broad macro effect.

Counterpoint

What could challenge this read

Growth may be unsustainable if reimbursement or CLIA/FDA hurdles arise.

Key entities

  • company
    bioAffinity Technologies, Inc.

    Biotech firm reporting sales growth.

  • partner
    AvMEDICAL

    Veteran‑owned distributor slated to expand government channel.

Read at source← All news

Related articles

OCT 13
$BIAFMed

bioAffinity Technologies to Present Sputum-Based Biomarker Data at CHEST 2026

bioAffinity Technologies will present data at CHEST 2026 on its investigational sputum test, which can detect lung inflammation protein biomarkers linked to asthma and COPD drug targets. The test, not yet FDA cleared, measures biomarkers like TSLP and IL-5, building on the company's CyPath Lung platform. According to the SEC filing, the test may help identify patients for biologic therapies with further validation.

tradingview.com1 min
OCT 8
$BIAFMedAI 8/10

WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies (NASDAQ: BIAF) raised $4M via a registered direct offering and private placement, selling shares and warrants at $6.122 each. Proceeds will support working capital and lung cancer test sales. WallachBeth Capital acted as placement agent. Closing expected October 9, 2026.

prnewswire.com4 min
OCT 8
$BIAFLow

bioAffinity Technologies, Inc. (BIAF): Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia

SEC EDGAR 8-K2 min
SEP 17
$BIAFMed

BIAF stock jumps on Hong Kong patent news, with recent low-float dynamics likely adding to volatility

bioAffinity Technologies (BIAF) shares rose 74.0% after Hong Kong granted a patent for its CyPath Lung lung-cancer detection technology, strengthening its IP position in Asia. The company's recent reverse stock split, reducing shares outstanding to 592,373, may have amplified the volatility. Several institutional investors adjusted their positions in Q2 2026, with notable additions from SABBY MANAGEMENT and BLACKROCK.

quiverquant.com2 min